Completed Studies

Completed accrual studies

  1. No.

    Participated Studies

    Total Accrual No.

    TCoC Accrual No.

    1

    A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

    1128

    37

    2

    A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 μg and 5 μg) delivered via Respimat® inhaler once daily in the evening over 48 weeks in children (6 to 11 years old) with moderate persistent asthma

     

    191

    3

    A 26-week treatment randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 (indacaterol / glycopyrronium bromide) compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary disease

     

    28

    4

    INFLOW - A multicenter non-randomized open-label observational study to assess effectiveness of indacaterol as measured by patient reported outcomes in COPD patients in real life settings

     

    100

    5

    Surveillance of Taiwan Obstructive Lung Disease (TOLD) ---Impact of GOLD new guideline strategy 2011 in the Management of COPD

     

    1096

    6

    A 26-week treatment multi-center, randomized, double-blind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 µg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

     

    55

    7

    A prospective, open-label, observational, non-interventional, multicenter, 52-week study on treatment effectiveness, safety and persistence with add-on omalizumab (Xolair®) in specific patient population with uncontrolled severe persistent asthma (EXACT)

     

    78

    8

    A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler

     

    22

    9

    A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; 5 μg / 5 μg) (delivered by the Respimat Inhaler)

     

    52

    10

    A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 μg and 5 μg) delivered via Respimat® inhaler once daily in the evening over 48 weeks in children (6 to 11 years old) with moderate persistent asthma

     

    191

    11

    The distribution of PCV13 Streptococcus pneumoniae serotype in radiology-proof community-acquired pneumonia (CAP)  adults over the age of 50 in selected hospitals and clinics

     

    100

    12

    A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Fosamil Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia

     

     

    11

    13

    Phase 3: A 24-week study to evaluate the efficacy and safety of fluticasone furoate (FF, GW685698)/ vilanterol trifenatate (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with placebo in subjects of Asian ancestry with Chronic Obstructive Pulmonary Disease.

     

     

    25

    14

    Phase 3: A clinical trial, in moderate COPD and a history of cardiovascular disease or risk increasing patients, to compare Fluticasone Furoate / Vilanterol Inhalation Powder 100 / 25mcg versus placebo for survival state assessment

     

     

    3

    15

    Phase 3: A 24-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the efficacy, safety, and tolarance of GSK573719/GW64244 125/25mcg, 62.5/25mcg and placebo  in COPD patients

     

     

    29

    16

    Phase 3: A 24-week treatment,  randomized, double-blind virtual, parallel-group trial, for administration of Tiotropium continued to have symptoms of chronic obstructive pulmonary disease (COPD) patients, comparing Umeclidinium / Vilanterol combination therapy

     

     

    15